Current News

Contact | Print version | PDF version | Send article | RSS-Feed

ProBioGen Announces Exclusive Licensing Agreement for its Proprietary Avian Cell Line AGE1.CR
Significant upfront and milestone payments plus royalties for four indications

10 Dec 2007 - ProBioGen AG announced the closing of an exclusive licensing agreement for its avian cell line AGE1.CR. The agreement was signed with an undisclosed US vaccine development company and covers a total of four indications, including different forms of influenza and three additional disease areas.
 
"This licensing agreement demonstrates the attractiveness of our unique cell line," said Michael Schlenk, CEO of ProBioGen. "We have shown that AGE1.CR is a superior vaccine production system compared to classical approaches such as egg-based production methods and other cell lines. Moreover, this agreement is another landmark in our strategy to increasingly focus on proprietary products, which are key value drivers in the context of international development collaborations."
 
AGE1.CR has been developed by ProBioGen to replace embryonated chicken eggs and chicken embryonic fibroblasts as substrates for production of human and animal vaccines. Primary chicken material has many disadvantages: It must be isolated freshly from specific pathogen free (SPF) flocks for each manufacturing run.